Correlation Between Enanta Pharmaceuticals and Bristol Myers

Can any of the company-specific risk be diversified away by investing in both Enanta Pharmaceuticals and Bristol Myers at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enanta Pharmaceuticals and Bristol Myers into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Enanta Pharmaceuticals and Bristol Myers Squibb, you can compare the effects of market volatilities on Enanta Pharmaceuticals and Bristol Myers and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enanta Pharmaceuticals with a short position of Bristol Myers. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enanta Pharmaceuticals and Bristol Myers.

Diversification Opportunities for Enanta Pharmaceuticals and Bristol Myers

0.12

Correlation Coefficient

Enanta Pharmaceuticals  Bristol Myers

Average diversification

The 3 months correlation between Enanta and Bristol is 0.12. Overlapping area represents the amount of risk that can be diversified away by holding Enanta Pharmaceuticals and Bristol Myers Squibb in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bristol Myers Squibb and Enanta Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enanta Pharmaceuticals are associated (or correlated) with Bristol Myers. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bristol Myers Squibb has no effect on the direction of Enanta Pharmaceuticals i.e., Enanta Pharmaceuticals and Bristol Myers go up and down completely randomly.

Pair Corralation between Enanta Pharmaceuticals and Bristol Myers

Given the investment horizon of 90 days Enanta Pharmaceuticals is expected to generate 3.41 times more return on investment than Bristol Myers. However, Enanta Pharmaceuticals is 3.41 times more volatile than Bristol Myers Squibb. It trades about 0.03 of its potential returns per unit of risk. Bristol Myers Squibb is currently generating about 0.07 per unit of risk. If you would invest  585.00  in Enanta Pharmaceuticals on December 29, 2024 and sell it today you would earn a total of  1.00  from holding Enanta Pharmaceuticals or generate 0.17% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Enanta Pharmaceuticals  vs.  Bristol Myers Squibb

Enanta Pharmaceuticals

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Enanta Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Enanta Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Bristol Myers Squibb

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal primary indicators, Bristol Myers may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Enanta Pharmaceuticals and Bristol Myers

The main advantage of trading using opposite Enanta Pharmaceuticals and Bristol Myers positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enanta Pharmaceuticals position performs unexpectedly, Bristol Myers can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will offset losses from the drop in Bristol Myers' long position.

The idea behind Enanta Pharmaceuticals and Bristol Myers Squibb pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.